Literature DB >> 2872593

Cushing's syndrome in patients with the Zollinger-Ellison syndrome.

P N Maton, J D Gardner, R T Jensen.   

Abstract

Reports of Cushing's syndrome in patients with the Zollinger-Ellison syndrome are rare, although up to 30 percent of gastrinomas contain ACTH-like immunoreactivity. We prospectively examined 75 patients with the Zollinger-Ellison syndrome for Cushing's syndrome. Three of 59 patients (5 percent) with the sporadic form of the Zollinger-Ellison syndrome had Cushing's syndrome, with severe symptoms due to ectopic production of ACTH. Each of these patients had metastatic gastrinoma, responded poorly to chemotherapy, and died within three years of the diagnosis of both syndromes. Three of 16 patients (19 percent) with the Zollinger-Ellison syndrome and multiple endocrine neoplasia type 1 had Cushing's syndrome due to pituitary production of ACTH, and their symptoms were mild. The gastrinoma in these patients was localized, and the prognosis was excellent. Thus, Cushing's syndrome is more common in patients with the Zollinger-Ellison syndrome than was previously reported, occurring in 8 percent of all cases. Furthermore, Cushing's syndrome in patients with sporadic Zollinger-Ellison syndrome and in those with multiple endocrine neoplasia type 1 differ in incidence, cause, clinical severity, extent of gastrinoma, the need for therapy, and prognosis. All patients with the Zollinger-Ellison syndrome and all patients with multiple endocrine neoplasia type 1 should be screened for Cushing's syndrome.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2872593     DOI: 10.1056/NEJM198607033150101

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  26 in total

Review 1.  The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors.

Authors:  Simon Schimmack; Bernhard Svejda; Benjamin Lawrence; Mark Kidd; Irvin M Modlin
Journal:  Langenbecks Arch Surg       Date:  2011-01-28       Impact factor: 3.445

2.  NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas.

Authors:  Matthew H Kulke; Lowell B Anthony; David L Bushnell; Wouter W de Herder; Stanley J Goldsmith; David S Klimstra; Stephen J Marx; Janice L Pasieka; Rodney F Pommier; James C Yao; Robert T Jensen
Journal:  Pancreas       Date:  2010-08       Impact factor: 3.327

Review 3.  Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies.

Authors:  Tetsuhide Ito; Lingaku Lee; Robert T Jensen
Journal:  Expert Opin Pharmacother       Date:  2016-09-23       Impact factor: 3.889

Review 4.  Management of functional neuroendocrine tumors of the pancreas.

Authors:  Kjell Öberg
Journal:  Gland Surg       Date:  2018-02

Review 5.  Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies.

Authors:  Robert T Jensen; Marc J Berna; David B Bingham; Jeffrey A Norton
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

6.  Cushing's syndrome in multiple endocrine neoplasia type 1.

Authors:  William F Simonds; Sarah Varghese; Stephen J Marx; Lynnette K Nieman
Journal:  Clin Endocrinol (Oxf)       Date:  2012-03       Impact factor: 3.478

Review 7.  Gastrinomas: Medical or Surgical Treatment.

Authors:  Jeffrey A Norton; Deshka S Foster; Tetsuhide Ito; Robert T Jensen
Journal:  Endocrinol Metab Clin North Am       Date:  2018-09       Impact factor: 4.741

Review 8.  Pancreatic neuroendocrine tumors: clinical features, diagnosis and medical treatment: advances.

Authors:  Tetsuhide Ito; Hisato Igarashi; Robert T Jensen
Journal:  Best Pract Res Clin Gastroenterol       Date:  2012-12       Impact factor: 3.043

9.  Argyrophil cell hyperplasia and a carcinoid tumour in the stomach of a patient with sporadic Zollinger-Ellison syndrome.

Authors:  G E Feurle
Journal:  Gut       Date:  1994-02       Impact factor: 23.059

Review 10.  Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advances.

Authors:  Tetsuhide Ito; Hisato Igarashi; Robert T Jensen
Journal:  J Gastroenterol       Date:  2012-08-11       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.